California's Biomedical Industry Lays Out Opposition to SB771
The chief lobbying group for the California biomedical industry Tuesday detailed its strong opposition to legislation that seeks to guarantee that California reaps an economic and health-related return on its $3 billion stem cell research investment.
David Gollaher, president of the 250-member organization, said the bill, SB771, will "create significant…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.